Oxford University’s COVID-19 vaccine, being developed in partnership with drugmaker AstraZeneca, has shown to be 70.4% effective in preliminary results from its Phase 3 clinical trial. That rate actually includes data from two different approaches to dosing, including one where two full-strength doses were applied, which was 62% effective, and a much more promising dosage … Continue reading Oxford University’s COVID-19 vaccine shows high efficacy, and is cheaper to make and easier to store